Skip to main content
SpringerLink
Log in

Combination therapy for erectile dysfunction: Where we are and what’s in the future

  • Published:
Current Urology Reports Aims and scope Submit manuscript

Abstract

Penile erection occurs in response to visual, olfactory, imaginative, and tactile stimuli initiated within the brain and/ or on the periphery. Responses to these stimuli are mediated by efferent autonomic outflow originating in the sacral spinal cord and transmitted by the cavernosal and penile nerves. A number of neurotransmitters can play an integral role in corpus cavernosum smooth muscle relaxation, in part regulating penile erection through increased smooth muscle synthesis of the secondary messengers cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). In addition to directacting agents, there are indirect-acting smooth musclerelaxing agents. Phosphodiesterase (PDE) inhibitors such as sildenafil act indirectly and require sexual stimulation and endogenous nitric oxide production to activate the cGMP pathway effectively. In contrast, agents such as prostaglandin E1 (PGE1) act directly on the trabecular smooth muscle, binding to specific e-prostanoid receptors and increasing cAMP synthesis. For this reason the direct-acting agents do not require sexual stimulation for efficacy. Combination pharmacotherapy has been used experimentally to treat erectile dysfunction for 25 years, using combinations of cAMP synthesis augmentors, smooth muscle relaxants and PDE inhibitors, and α-blockers administered via intracavernosal injection. The present era of oral pharmacotherapy treatment has resulted in significant awareness in the field of sexual dysfunction; however, a single agent may not be ideal to sustain penile rigidity, especially if comorbidities and severity of erectile dysfunction are accounted for. The rationale for and recent reports on combination therapy are presented in this review.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Nehra A, Barrett DM, Moreland RB: Pharmacotherapeutic advances in the treatment of erectile dysfunction. Mayo Clin Proc 1999, 74:709–722. This peer-reviewed publication discusses forthcoming novel therapies and includes a review of the epidemiology and pathophysiology of ED.

    Article  PubMed  CAS  Google Scholar 

  2. Moreland RB, Albadawi H, Bratton C, et al.: O2-dependent prostanoid synthesis activates functional PGE receptors on human corpus cavernosum smooth muscle cells. Am J Physiol Heart Circ Physiol 2001, 281:H552-H558. This article discusses the activation of PGE receptors and their relevance to oxygen intention.

    PubMed  CAS  Google Scholar 

  3. Goldstein I, Lue TF, Padma-Nathan H, et al.: Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group. N Engl J Med 1998, 338:1397–1404. This is an excellent article discussing how sildenafil citrate has been shown to have an enhanced efficacy rate across patient populations with ED.

    Article  PubMed  CAS  Google Scholar 

  4. Derry FA, Dinsmore WW, Fraser M, et al.: Efficacy and safety of oral sildenafil (Viagra) in men with erectile dysfunction caused by spinal cord injury. Neurology 1998, 51:1629–1633.

    PubMed  CAS  Google Scholar 

  5. Maytom MC, Derry FA, Dinsmore WW, et al.: A two-part pilot study of sildenafil (Viagra) in men with erectile dysfunction caused by spinal cord injury. Spinal Cord 1999, 37:110–116.

    Article  PubMed  CAS  Google Scholar 

  6. Rendell MS, Rajfer J, Wicker PA, Smith MD: Sildenafil for treatment of erectile dysfunction in men with diabetes: a randomized controlled trial. Sildenafil Diabetes Study Group. JAMA 1999, 281:421–426. There are approximately 8 to 10 million patients with diagnosed diabetes mellitus in the United States, and sexual dysfunction remains a major issue for these patients. This randomized-controlled trial laid the groundwork for a number of other trials examining the treatment of diabetes-related ED with PDE-5 inhibitors.

    Article  PubMed  CAS  Google Scholar 

  7. Marks LS, Duda C, Dorey FJ, et al.: Treatment of erectile dysfunction with sildenafil. Urology 1999, 53:19–24.

    Article  PubMed  CAS  Google Scholar 

  8. Hellstrom WJ, Bennett AH, Gesundheit N, et al.: A doubleblind, placebo-controlled evaluation of the erectile response to transurethral alprostadil. Urology 1996, 48:851–856.

    Article  PubMed  CAS  Google Scholar 

  9. Padma-Nathan H, Hellstrom WJ, Kaiser FE, et al.: Treatment of men with erectile dysfunction with transurethral alprostadil. Medicated Urethral System for Erection (MUSE) Study Group. N Engl J Med 1997, 336:1–7.

    Article  PubMed  CAS  Google Scholar 

  10. Hatzichristou DG, Saenz de Tejada I, Kupferman S, et al.: In vivo assessment of trabecular smooth muscle tone, its application in pharmacocavernosometry, and analysis of intracavernosal pressure determinants. J Urol 1995, 153:1126–1135.

    Article  PubMed  CAS  Google Scholar 

  11. Porst H: Transurethral alprostadil with MUSE (medicated urethral system for erection) vs intracavernous alprostadil: a comparative study in 103 patients with erectile dysfunction. Int J Impot Res 1997, 9:187–192.

    Article  PubMed  CAS  Google Scholar 

  12. Kim NN, Huang Y, Moreland RB, et al.: Cross-regulation of intracellular cGMP and cAMP in cultured human corpus cavernosum smooth muscle cells. Mol Cell Biol Res Comm 2000, 4:10–14. This is an excellent manuscript discussing cross-regulation or crosstalk between cAMP and cGMP, thus laying the foundation for future accommodation therapies for the treatment of ED.

    Article  CAS  Google Scholar 

  13. Escrig A, Marin R, Mas M: Repeated PGE1 treatment enhances nitric oxide and erection responses to nerve stimulation in the rat penis by upregulating constitutive NOS isoforms. J Urol 1999, 162:2205–2210.

    Article  PubMed  CAS  Google Scholar 

  14. Traish A, Kim NN, Huang YH, et al.: Cyclic AMP regulates mRNA expression of á-1d and á-2a adrenergic receptors in cultured human corpus cavernosum smooth muscle cells. Int J Impot Res 2000, 12:S41-S47.

    Article  PubMed  Google Scholar 

  15. Mydlo JH, Volpe MA, Macchia RJ: Initial results utilizing combination therapy for patients with a suboptimal response to either alprostadil or sildenafil monotherapy. Eur Urol 2000, 38:30–34.

    Article  PubMed  CAS  Google Scholar 

  16. Mydlo JH, Volpe MA, Macchia RJ: Results from different patient populations using combined therapy with alprostadil and sildenafil: predictors of satisfaction. BJU Int 2000, 86:469–473. Sildenafil citrate and alprostadil are effective agents that mediate smooth muscle relaxation via the cGMP and cAMP pathways, respectively. These agents have demonstrated significant efficacy rates among different populations comprised of multiple patient subgroups.

    Article  PubMed  CAS  Google Scholar 

  17. Montorsi F, Maga T, Strambi LF, et al.: Sildenafil taken at bedtime significantly increases nocturnal erections: results of a placebo-controlled study. Urology 2000, 56:906–911.

    Article  PubMed  CAS  Google Scholar 

  18. Nehra A, Blute ML, Barrett DM, Moreland RB: Rationale for combination therapy of intraurethral PGE1 and sildenafil in the salvage of erectile dysfunction patients desiring noninvasive therapy. Int J Impot Res 2002, 14:S38-S42. This article discusses the use of PGE1 and sidenafil citrate as combination therapy to treat ED in the patient who desires noninvasive therapy. The authors demonstrate that it is possible to enhance further or optimize erectile function, even when monotherapy has failed.

    Article  PubMed  Google Scholar 

  19. Kaplan SA, Reis RB, Kohn IJ, et al.: Combination therapy using oral á-blockers and intracavernosal injection in men with erectile dysfunction. Urology 1998, 52:739–743.

    Article  PubMed  CAS  Google Scholar 

  20. Doherty PC, Bivalacqua TJ, Champion HC, et al.: Direct effects of selective type 5 phosphodiesterase inhibitors alone or with other vasodilators on the erectile response in cats. J Urol 2001, 165:1004–1009.

    Article  PubMed  CAS  Google Scholar 

  21. Andersson KE, Gemalmaz H, Waldeck K, et al.: The effect of sildenafil on apomorphine-evoked increases in intracavernous pressure in the awake rat. J Urol 1999, 161:1707–1712.

    Article  PubMed  CAS  Google Scholar 

  22. Price DE, Gingell JC, Gepi-Attee S, et al.: Sildenafil: study of a novel oral treatment for erectile dysfunction in diabetic men. Diabet Med 1998, 15:821–825.

    Article  PubMed  CAS  Google Scholar 

  23. Gans WH, Zaslau S, Wheeler S, et al.: Efficacy and safety of oral sildenafil in men with erectile dysfunction and spinal cord injury. J Spinal Cord Med 2001, 24:35–40.

    PubMed  CAS  Google Scholar 

  24. Sanchez Ramos A, Vidal J, Jauregui ML, et al.: Efficacy, safety, and predictive factors of therapeutic success with sildenafil for erectile dysfunction in patients with different spinal cord injuries. Spinal Cord 2001, 39:637–643. Patients with spinal cord injuries have varying degrees of ED, depending upon the level of their cervical, thoracolumbar, or lumbar injuries. Here the authors present the efficacy, safety, and predictive factors of PDE-5 inhibitors for the treatment of ED after SCI.

    Article  Google Scholar 

  25. Olsson AM, Persson CA: Efficacy and safety of sildenafil citrate for the treatment of erectile dysfunction in men with cardiovascular disease. Int J Clin Pract 2001, 55:171–176. Cardiovascular disease is a significant comorbidity in patients with ED. The authors discuss efficacy and safety, two very important aspects of the use of PDE-5 inhibitors in patients with known cardiovascular disease.

    PubMed  CAS  Google Scholar 

  26. Schmidt DM, Schurch B, Hauri D: Sildenafil in the treatment of sexual dysfunction in spinal cord-injured male patients. Eur Urol 2000, 38:184–193.

    Article  Google Scholar 

  27. Giuliano F, Hultling C, el Masry WS, et al.: Sildenafil citrate (Viagra): a novel oral treatment for erectile dysfunction caused by traumatic spinal cord injury. Int J Clin Pract 1999, 102:24–26.

    CAS  Google Scholar 

  28. Lowentritt BH, Scardino PT, Miles BJ, et al.: Sildenafil citrate after radical retropubic prostatectomy. J Urol 1999, 162:1614–1617.

    Article  PubMed  CAS  Google Scholar 

  29. Zippe CD, Kedia AW, Kedia K, et al.: Treatment of erectile dysfunction after radical prostatectomy with sildenafil citrate (Viagra). Urology 1998, 52:963–966. This is an excellent article with respect to the radical prostatectomy group and the role of PDE-5 inhibitors in the treatment of ED.

    Article  PubMed  CAS  Google Scholar 

  30. Zelefsky MJ, McKee AB, Lee H, Leibel SA: Efficacy of oral sildenafil in patients with erectile dysfunction after radiotherapy for carcinoma of the prostate. Urology 1999, 53:775–778.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, Mayo Clinic, 200 First Street SW, 55905, Rochester, MN, USA

    Ajay Nehra MD

Authors
  1. Ajay Nehra MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Haluk Kulaksizoglu MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Nehra, A., Kulaksizoglu, H. Combination therapy for erectile dysfunction: Where we are and what’s in the future. Curr Urol Rep 3, 467–470 (2002). https://doi.org/10.1007/s11934-002-0099-z

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11934-002-0099-z

Keywords

Search

Navigation